

Bing Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1863202/publications.pdf>

Version: 2024-02-01

84
papers

805
citations

567281

15
h-index

677142

22
g-index

106
all docs

106
docs citations

106
times ranked

1028
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterozygous missense mutations in the GLRX5 gene cause sideroblastic anemia in a Chinese patient. <i>Blood</i> , 2014, 124, 2750-2751.	1.4	40
2	Chemical constituents of <i>Ligusticum chuanxiong</i> and their anti-inflammation and hepatoprotective activities. <i>Bioorganic Chemistry</i> , 2020, 101, 104016.	4.1	35
3	Long-term follow-up study of porcine anti-human thymocyte immunoglobulin therapy combined with cyclosporine for severe aplastic anemia. <i>European Journal of Haematology</i> , 2016, 96, 291-296.	2.2	32
4	Evaluation of the Efficiency of the Reticulocyte Hemoglobin Content on Diagnosis for Iron Deficiency Anemia in Chinese Adults. <i>Nutrients</i> , 2017, 9, 450.	4.1	31
5	Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 715-725.	5.5	30
6	Sirolimus is effective for primary relapsed/refractory autoimmune cytopenia: a multicenter study. <i>Experimental Hematology</i> , 2020, 89, 87-95.	0.4	30
7	Ferulic acid derivatives from <i>Ligusticum chuanxiong</i> . <i>FÄ-toterapÄ-c</i> , 2018, 125, 147-154.	2.2	28
8	A concise approach for determining the relative configuration of H-7 and H-8 in 8,4 ² -oxyneolignans by ¹ H NMR spectroscopy. <i>Organic Chemistry Frontiers</i> , 2019, 6, 886-891.	4.5	27
9	A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. <i>International Journal of Hematology</i> , 2016, 103, 649-654.	1.6	26
10	Comparison of gene mutation spectrum of thalassemia in different regions of China and Southeast Asia. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e680.	1.2	25
11	Successful treatment of refractory/relapsed acquired pure red cell aplasia with sirolimus. <i>Annals of Hematology</i> , 2018, 97, 2047-2054.	1.8	24
12	Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 181, 111595.	5.5	23
13	Current Treatment Patterns of Aplastic Anemia in China: A Prospective Cohort Registry Study. <i>Acta Haematologica</i> , 2019, 142, 162-170.	1.4	22
14	Identification of novel mutations in HFE, HFE2, TfR2, and SLC40A1 genes in Chinese patients affected by hereditary hemochromatosis. <i>International Journal of Hematology</i> , 2017, 105, 521-525.	1.6	20
15	Identification of four SLC19A2 mutations in four Chinese thiamine responsive megaloblastic anemia patients without diabetes. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 52, 203-204.	1.4	19
16	Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 360-367.	1.7	18
17	Comparative study of porcine anti-human lymphocyte immunoglobulin and rabbit anti-human thymocyte immunoglobulin as a first-line treatment of acquired severe aplastic anemia. <i>Leukemia Research</i> , 2018, 65, 55-60.	0.8	17
18	Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma. <i>Leukemia Research</i> , 2014, 38, 188-193.	0.8	16

#	ARTICLE	IF	CITATIONS
19	Clinical features of <i>DDX41</i> mutation-related diseases: a systematic review with individual patient data. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110324.	2.5	15
20	Vasoactive Intestinal Peptide Ameliorates Synovial Cell Functions of Collagen-Induced Arthritis Rats by Down-Regulating NF- κ B Activity. <i>Immunological Investigations</i> , 2005, 34, 153-169.	2.0	14
21	Diagnostic Splenectomy in Patients with Fever of Unknown Origin and Splenomegaly. <i>Acta Haematologica</i> , 2008, 119, 83-88.	1.4	14
22	Phthalide derivatives from <i>Ligusticum chuanxiong</i> . <i>RSC Advances</i> , 2017, 7, 37478-37486.	3.6	14
23	Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 5581-5594.	6.7	14
24	hERG optimizations of IMB1603, discovery of alternative benzothiazinones as new antitubercular agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 208-217.	5.5	13
25	Autoimmune disease-associated non-Hodgkin's lymphoma—a large retrospective study from China. <i>Annals of Hematology</i> , 2019, 98, 445-455.	1.8	13
26	Telomerase gene mutation screening in Chinese patients with aplastic anemia. <i>Leukemia Research</i> , 2010, 34, 258-260.	0.8	12
27	Congenital sideroblastic anemia: Advances in gene mutations and pathophysiology. <i>Gene</i> , 2018, 668, 182-189.	2.2	12
28	Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 579221.	2.8	11
29	Comparison of frontline treatment with intensive immunosuppression therapy and HLA-haploidentical hematopoietic stem cell transplantation for young patients with severe aplastic anemia: A meta analysis. <i>Leukemia Research</i> , 2020, 88, 106266.	0.8	9
30	Gene mutation profile in patients with acquired pure red cell aplasia. <i>Annals of Hematology</i> , 2020, 99, 1749-1754.	1.8	9
31	Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial. <i>Leukemia</i> , 2022, 36, 1351-1360.	7.2	9
32	Primary cutaneous diffuse large B-cell lymphoma (leg type) after renal allograft: case report and review of the literature. <i>International Journal of Hematology</i> , 2009, 89, 113-117.	1.6	8
33	Tacrolimus is effective in relapsed/refractory autoimmune cytopenias: results of a single-center retrospective study. <i>Hematology</i> , 2020, 25, 478-483.	1.5	8
34	Successful sirolimus treatment of patients with pure red cell aplasia complicated with renal insufficiency. <i>Annals of Hematology</i> , 2020, 99, 737-741.	1.8	8
35	¹¹ C-acetate positron emission tomography is more precise than ¹⁸ F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma. <i>Scientific Reports</i> , 2021, 11, 22188.	3.3	8
36	A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210851.	2.5	8

#	ARTICLE	IF	CITATIONS
37	Dihydrofolate Reductase Transcript Level Is Not Suitable for Methotrexate-Resistance Prediction in Choriocarcinoma Cell Line. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1259-1263.	2.5	7
38	Gene spectrum analysis of thalassemia for people residing in northern China. <i>BMC Medical Genetics</i> , 2019, 20, 86.	2.1	7
39	Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia. <i>Annals of Hematology</i> , 2020, 99, 1141-1143.	1.8	7
40	Polymorphism of the <i>ABO</i> gene associate with thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria. <i>Oncotarget</i> , 2017, 8, 92411-92419.	1.8	7
41	Identification of FECH gene multiple variations in two Chinese patients with erythropoietic protoporphyria and a review. <i>Journal of Zhejiang University: Science B</i> , 2016, 17, 813-820.	2.8	6
42	Novel phenylpropanoid amino acid adducts from <i>Ligusticum chuanxiong</i> . <i>Organic Chemistry Frontiers</i> , 2018, 5, 1423-1430.	4.5	6
43	Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China. <i>Annals of Hematology</i> , 2019, 98, 143-150.	1.8	6
44	Ultra-small platinum nanoparticles on gold nanorods induced intracellular ROS fluctuation to drive megakaryocytic differentiation of leukemia cells. <i>Biomaterials Science</i> , 2020, 8, 6204-6211.	5.4	6
45	Agranulocytosis and mixed type autoimmune hemolytic anemia in primary Sjögren's syndrome: a case report and review of the literature. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 1351-1353.	1.9	5
46	Ligubenzocycloheptanone A, a Novel Tricyclic Butenolide with a 6/7/5 Skeleton from <i>Ligusticum chuanxiong</i> . <i>Scientific Reports</i> , 2016, 6, 28783.	3.3	5
47	Multicentric Castleman's disease presenting with multiple nodes in lungs: a case report and literature review. <i>International Journal of Hematology</i> , 2008, 88, 278-282.	1.6	4
48	CR1 gene polymorphisms in Chinese patients with paroxysmal nocturnal hemoglobinuria. <i>Gene</i> , 2018, 659, 149-154.	2.2	4
49	Langerhans cell histiocytosis and Erdheim-Chester disease overlap syndrome with bone marrow involvement and type 2 diabetes mellitus. <i>Annals of Hematology</i> , 2018, 97, 189-192.	1.8	4
50	Immunosuppression therapy is effective for both acquired tumor-associated and primary pure red cell aplasia: a match pair case-control study. <i>Annals of Hematology</i> , 2020, 99, 1485-1491.	1.8	4
51	Comparison of Hypomethylator Monotherapy with Hypomethylator plus Chemotherapy for Intermediate/High-Risk MDS or AML: A Meta-Analysis. <i>Journal of Cancer</i> , 2020, 11, 2972-2980.	2.5	4
52	Advances in Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 301-307.	1.2	4
53	Mutational landscape and its clinical significance in paroxysmal nocturnal hemoglobinuria. <i>Blood Cancer Journal</i> , 2021, 11, 58.	6.2	4
54	Verification of the Cut-off Value of the Reticulocyte Hemoglobin Content to Diagnose Iron Deficiency. <i>Biomedical and Environmental Sciences</i> , 2020, 33, 543-546.	0.2	4

#	ARTICLE	IF	CITATIONS
55	Outcome of anti-thymocyte immunoglobulin plus cyclosporine A for severe aplastic anaemia with chronic hepatitis B virus infection. <i>Annals of Hematology</i> , 2017, 96, 581-587.	1.8	3
56	Eltrombopag is effective in patients with relapse/refractory aplastic anemia—report from a single center in China. <i>Annals of Hematology</i> , 2020, 99, 2755-2761.	1.8	3
57	Renal Involvement and HBV Infection Are Common in Chinese Patients With Cryoglobulinemia. <i>Frontiers in Immunology</i> , 2021, 12, 580271.	4.8	3
58	High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies. <i>Aging</i> , 2021, 13, 11120-11134.	3.1	3
59	A Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Hetrombopag in Patients with Severe Aplastic Anemia (SAA). <i>Blood</i> , 2020, 136, 3-4.	1.4	3
60	Effective Tacrolimus Treatment for Patients with Non-Severe Aplastic Anemia That is Refractory/Intolerant to Cyclosporine A: A Retrospective Study. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 5711-5719.	4.3	3
61	Effective treatment of refractory acquired pure red blood cell aplasia with eltrombopag and sirolimus: a case report. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072094014.	2.5	2
62	Clinical characteristics of 512 eculizumab-naïve paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study. <i>Hematology</i> , 2022, 27, 113-121.	1.5	2
63	Plasma lipidome acts as diagnostic marker and predictor for cyclosporin response in patients with aplastic anemia. <i>Clinical and Experimental Medicine</i> , 2022, , 1.	3.6	2
64	Proliferative Capacity of Single Isolated CD34+ Hematopoietic Stem/Progenitor Cells in Paroxysmal Nocturnal Hemoglobinuria. <i>International Journal of Hematology</i> , 2001, 74, 42-52.	1.6	1
65	Successful treatment of an adult with Kasabach-Merritt syndrome using thalidomide, vincristine, and prednisone. <i>Journal of International Medical Research</i> , 2019, 47, 1810-1814.	1.0	1
66	Comparisons Between Frontline Therapy and a Combination of Eltrombopag Plus Immunosuppression Therapy and Human Leukocyte Antigen-Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 614965.	2.8	1
67	Gene Mutation Profile in Patients with Acquired Pure Red Cell Aplasia. <i>Blood</i> , 2018, 132, 2592-2592.	1.4	1
68	Stanozolol and Danazol Have Different Effects on Hematopoiesis in Murine Model of Immune-Mediated Bone Marrow Failure. <i>Blood</i> , 2019, 134, 2506-2506.	1.4	1
69	Very Low-Dose Decitabine Is Effective in Treating Intermediate or High Risk Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 5536-5536.	1.4	1
70	Recombinant Human Thrombopoietin Accelerates the Recovery of Platelet in Patients With Lower-Risk Myelodysplastic Syndrome: A Proof-of-Concept Study. <i>Frontiers in Oncology</i> , 2021, 11, 721764.	2.8	1
71	Thymidylate synthase mRNA expression does not predict resistance to floxuridine in a choriocarcinoma cell line. <i>Journal of reproductive medicine, The</i> , 2010, 55, 247-52.	0.2	1
72	Competing Endogenous RNA Network in Non-Keloid-Prone Individuals During Wound Healing. <i>Journal of Craniofacial Surgery</i> , 2022, 33, 29-34.	0.7	1

#	ARTICLE	IF	CITATIONS
73	Hereditary intrinsic factor deficiency in China caused by a novel mutation in the intrinsic factor gene—a case report. <i>BMC Medical Genetics</i> , 2020, 21, 221.	2.1	0
74	Observational Study of Magnetic Resonance Imaging Monitoring in Patients with Aplastic Anemia (AA) and Low or Int-1 Risk of Myelodysplastic Syndromes(MDS) Complicated with Iron Overload. <i>Blood</i> , 2016, 128, 4825-4825.	1.4	0
75	Possible Risk Factors of Thrombosis in Chinese Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2016, 128, 2427-2427.	1.4	0
76	Real-World Effectiveness and Safety of Eltrombopag in Patients with Aplastic Anemia: A Chinese Nationwide Survey. <i>Blood</i> , 2019, 134, 5020-5020.	1.4	0
77	The Comparison of Hypomethylating Agents (HMA) Monotherapy with HMA Combined with Intensive Chemotherapy for Intermediate / High-Risk MDS or AML. <i>Blood</i> , 2019, 134, 3903-3903.	1.4	0
78	Dose of Deferasirox Correlates with Effects but Is Different in Low-Risk Myelodysplastic Syndrome and Aplastic Anemia. <i>Blood</i> , 2021, 138, 3075-3075.	1.4	0
79	Plasma Lipidome Acts As Diagnostic Marker and Predictor for Cyclosporin Response in Patients with Aplastic Anemia. <i>Blood</i> , 2021, 138, 2199-2199.	1.4	0
80	Efficacy and Safety of Eltrombopag with or without Immunosuppressant in Patients with Relapsed/Refractory Acquired Aplastic Anemia: A Real-World Experience. <i>Blood</i> , 2021, 138, 1124-1124.	1.4	0
81	Recombinant Human Thrombopoietin Accelerates the Recovery of Platelet in Patients with Lower-Risk Myelodysplastic Syndrome: A Prospective Cohort Study. <i>Blood</i> , 2021, 138, 1525-1525.	1.4	0
82	Plasma Concentration of Eltrombopag Correlated with the Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Center Study in China. <i>Blood</i> , 2020, 136, 9-9.	1.4	0
83	Detection of Myeloid and Clonal Expansion Related Gene Mutations By Whole-Exome Sequencing in Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2020, 136, 10-10.	1.4	0
84	Impaired erythropoietin response to anemia in patients with lymphocytic malignancies. <i>Chinese Medical Sciences Journal</i> , 2007, 22, 203-4.	0.4	0